Systemic therapy for advanced carcinoid tumors: where do we go from here?

Area of Science:

• Oncology
• Endocrinology

Background:

• Carcinoid tumors are generally indolent but pose treatment challenges in advanced stages.
• Current treatments for advanced carcinoid disease, including somatostatin analogs (SSTa) and chemotherapy, have limited efficacy.
• There is a significant unmet need for effective systemic therapies with antitumor activity in advanced carcinoid cancer.

Purpose of the Study:

• To review the current therapeutic landscape for advanced carcinoid tumors.
• To identify challenges and unmet needs in managing advanced carcinoid disease.
• To explore emerging therapeutic strategies and targets for carcinoid tumors.

Main Methods:

• Literature review of existing treatments for carcinoid tumors.
• Analysis of the efficacy and limitations of current therapies like SSTa, chemotherapy, and interferon.
• Exploration of novel therapeutic targets and agents under investigation, including VEGF and mTOR inhibitors.

Main Results:

• Somatostatin analogs (SSTa) are effective for symptom control but lack significant antitumor activity.
• Limited evidence supports the efficacy of chemotherapy and interferon in advanced carcinoid.
• Everolimus shows a trend toward improved progression-free survival but is not approved.
• Peptide receptor radionuclide therapy shows potential but requires further validation.

Conclusions:

• Advanced carcinoid tumor treatment remains a significant challenge with limited effective systemic options.
• Novel therapeutic strategies targeting VEGF, mTOR, and other signaling pathways are under investigation.
• Optimizing patient selection through biomarkers may improve treatment outcomes for advanced carcinoid.